Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2000-02-09
2002-04-23
Criares, Theodore J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
06376479
ABSTRACT:
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not Applicable.
BACKGROUND OF THE INVENTION
This invention relates to a method for treating or preventing hyperparathyroidism utilizing an active vitamin D compound.
Hyperparathyroidism is a generalized disorder resulting from excessive secretion of parathyroid hormone (PTH) by one or more parathyroid glands. It is thus characterized by elevated blood levels of parathyroid hormone. Typically, one or more parathyroid glands reveal a marked enlargement. In the case of primary hyperparathyroidism, the glandular enlargement is usually due to a neoplasm or tumor. In the case of secondary hyperparathyroidism, the parathyroid gland hyperplasia typically occurs because of resistance to the metabolic actions of the hormone. Secondary hyperparathyroidism occurs in patients with, e.g., renal failure, osteomalacia, and intestinal malabsorption syndrome. In both primary and secondary hyperparathyroidism, bone abnormalities, e.g., the loss of bone mass or decreased mineral content, are common and renal damage is possible. Hyperparathyroidism is thus also characterized by abnormal calcium, phosphorus and bone metabolism.
It has long been known that vitamin D plays a critical role regulating calcium metabolism. The discovery of the active forms of vitamin D in the 1970's [M. F. Holick et al.,
Proc. Natl. Acad. Sci. USA
68, 803-804 (1971); G. Jones et al.,
Biochemistry
14, 1250-1256 (1975)] and active vitamin D analogues [M. F. Holick et al.,
Science
180, 190, 191 (1973); H. Y. Lam et al.,
Science
186, 1038-1040 (1974)], caused much excitement and speculation about the usefulness of these compounds in the treatment of bone depletive disorders.
Animal and early clinical studies examining the effects of these active vitamin D compounds suggested that such agents would be useful in restoring calcium balance. However, the best indicator of the efficacy of vitamin D compounds to prevent or treat depletive bone disorders is bone itself (or, in the case of renal osteodystrophy, serum levels of parathyroid hormone (PTH)) rather than calcium absorption or calcium balance. Certain clinical studies with 1&agr;,25-(OH)
2
vitamin D
3
, and 1&agr;-OH vitamin D
3
indicate that the ability of these agents to restore lost bone mass or bone mineral content is dose-related. [See, S. M. Ott, C. H. Chesnut,
Annals of Int. Med
1989; 110:267-274; J. C. Gallagher et al.,
Annals of Int. Med.
1990; 113:649-655; J. Aloia et al.,
Amer. J Med
84:401-08 (1988)] M. Shiraki et al.,
Endocrinol. Japan
32, 305-315 (1985)].
These clinical studies also indicate that at the dosage ranges required for these agents to be truly effective, toxicity in the form of hypercalcemia and hypercalciuria becomes a major problem. Attempts to increase the amount of 1&agr;,25-(OH)
2
vitamin D
3
above 0.5 &mgr;g/day have frequently resulted in toxicity. At dosage levels below 0.5 &mgr;g/day, clinically significant effects on bone are rarely observed. [See G. F. Jensen et al.,
Clin. Endocrinol.
16, 515-524 (1982); C. Christiansen et al.,
Eur. J Clin.
Invest. 11, 305-309 (1981)]. Doses of 2 &mgr;g/day of 1&agr;-OH vitamin D
3
were found to have efficacy in increasing bone mass in patients exhibiting senile osteoporosis [O. H. Sorensen et al.,
Clin. Endocrinol.
7, 169S-175S (1977)]. Data from clinical studies in Japan, a population that has low calcium intake, indicate that efficacy is found with 1&agr;-OH vitamin D
3
when administered at 1 &mgr;g/day [M. Shiraki et al.,
Endocrinol. Japan.
32:305-315 (1985); H. Orimo et al.,
Bone and Mineral
3, 47-52 (1987)]. However, at 2 &mgr;g/day, toxicity with 1&agr;-OH vitamin D
3
occurs in approximately 67 percent of the patients, and at 1 &mgr;g/day this percentage is approximately 20 percent.
Thus, the prior art teaches that due to their toxicity, 1-hydroxylated vitamin D compounds can only be administered at dosages that are, at best, modestly beneficial in preventing or treating loss of bone or bone mineral content. Indeed, Aloia recommends that alternative routes of administration be sought which might avoid the toxicity problems and allow higher dosage levels to be achieved. [J. Aloia et al.,
Amer. J Med
84:401-408 (1988)]. Despite reported toxicities of 1&agr;-OH vitamin D
3
and 1&agr;,25-(OH)
2
vitamin D
3
, these two compounds remain the drugs of choice for many bone depletive disease treatments.
As to secondary hyperparathyroidism and its occurrence in renal failure, at present, in the United States, end stage renal disease afflicts approximately 200,000 individuals. In this disease, there is a progressive loss of cells of the proximal nephrons, the primary site for the synthesis of the vitamin D hormones (collectively “1&agr;,25-(OH)
2
D”) from 25-hydroxyvitamin D
3
and 25-hydroxyvitamin D
2
. In addition, the loss of functioning nephrons leads to retention of excess phosphorus which reduces the activity of the renal 25-hydroxyvitamin D-1&agr;-hydroxylase, the enzyme which catalyzes the reaction to produce the D hormones. These two events account for the low serum levels of 1&agr;,25-(OH)
2
D commonly found in patients with mild to moderate end stage renal disease.
Reduced serum levels of 1&agr;,25-(OH)
2
D cause increased, and ultimately excessive, secretion of PTH by direct and indirect mechanisms. The resulting hyperparathyroidism leads to markedly increased bone turnover and its sequela of renal osteodystrophy, which may include a variety of other diseases, such as, osteitis fibrosa cystica, osteomalacia, osteoporosis, extraskeletal calcification and related disorders, e.g., bone pain, periarticular inflammation and Mockerberg's sclerosis. Reduced serum levels of 1&agr;,25-(OH)
2
D also can cause muscle weakness and growth retardation with skeletal deformities (most often seen in pediatric patients).
Previous clinical studies of hormonally active vitamin D drugs in end stage renal disease patients have focused on compounds derived from vitamin D
3
. 1&agr;,25-(OH)
2
D
3
and 1&agr;-OH-D
3
are the major approved forms of 1&agr;-hydroxylated vitamin D for treatment or prevention, although these drugs are not currently approved in all major pharmaceutical markets. Use of 1&agr;,25-(OH)
2
D
3
and 1&agr;-OH-vitamin D
3
as replacement therapy seeks to treat or prevent renal osteodystrophy by treating or preventing hyperparathyroidism in end stage renal disease patients. As noted above, 1&agr;,25-(OH)
2
D
3
often causes toxic side effects (hypercalcemia and hyperphosphatemia) at dosages above 0.5 &mgr;g, especially when concomitantly administered calcium phosphate binders are used to control serum phosphorus. The minimum effective dose for preventing hyperparathyroidism is in the range of 0.25 to 0.50 &mgr;g/day; most patients respond to oral treatment doses of 0.5 to 1.0 &mgr;g/day or intravenous doses between 0.5 and 3.0 &mgr;g three times per week. As described above, the other commonly used vitamin D drug is 1&agr;-OH-D
3
which often causes toxic effects at dosages over 1.0 &mgr;g/day, especially when used with calcium phosphate binders. The minimum effective dosage for preventing hyperparathyroidism is in the range of 0.25 to 1.0 &mgr;g/day, and most patients require treatment dosages of 1.0 &mgr;g/day or more. When either drug, 1&agr;,25-(OH)
2
D
3
or 1&agr;-OH-D
3
, is administered in higher dosages, both efficacy and toxicity are found to increase. Thus, the hormonally active vitamin D
3
compounds are limited in their therapeutic usefulness due to their inherent toxicities.
To reduce the incidence of toxic side effects with 1&agr;,25-(OH)
2
D
3
or 1&agr;-OH-D
3
, a low calcium dialysate with an ionized calcium concentration of 1.25 mM has been developed. However, it has been found that use of the low calcium dialysate has lead to higher serum PTH and phosphorus levels in patients who do not receive increased doses of oral calcium supplements and phosphate binders. When the dosages of calcium supplement
Bishop Charles W.
Knutson Joyce C
Bone Care International, Inc.
Criares Theodore J.
Welch Teresa J.
LandOfFree
Method for treating and preventing hyperparathyroidism does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating and preventing hyperparathyroidism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating and preventing hyperparathyroidism will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2863566